Get the Stockscreener App
1.98
1.02%
0.02
After Hours:
2.05
0.07
+3.54%
Nls Pharmaceutics Ltd stock is traded at $1.98, with a volume of 230.56K.
It is up +1.02% in the last 24 hours and down -27.21% over the past month.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$1.96
Open:
$1.85
24h Volume:
230.56K
Relative Volume:
0.21
Market Cap:
$5.84M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-3.96
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
+6.45%
1M Performance:
-27.21%
6M Performance:
-79.55%
1Y Performance:
-89.69%
1-Day Range:
$1.85
$2.019
1-Week Range:
$1.71
$2.06
52-Week Range:
$1.71
$20.80
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.98 | 5.84M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
NLS Pharmaceutics Submits Research Abstracts to ASCP 2025 - TipRanks
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment - TipRanks
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
NLS Pharmaceutics and Kadimastem Announce Initial Closing of $500,000 Fundraising Effort for Merger - HPBL
NLS Pharmaceutics and Kadimastem Move Forward with Merger to Create Nasdaq-Traded Biotechnology Company - HPBL
NLS Pharmaceutics and Kadimastem Merger & Financing Update – Market - HPBL
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - The Malaysian Reserve
Kadimastem Calls for a Special General Meeting of Shareholders t - GuruFocus.com
NLS Pharmaceutics and Kadimastem Move Toward Merger Approval - TipRanks
NLS Pharmaceutics Completes Initial $500K Financing to Advance Kadimastem Merger - Sleep Review
NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising - Yahoo Finance
NLS Pharmaceutics Announces Extraordinary Shareholders’ Meeting Results – Market - HPBL
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - The Malaysian Reserve
NLS Pharmaceutics Secures Premium-Priced $500K Investment, Advances Kadimastem Merger Plans - StockTitan
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
NLS Pharmaceutics Shareholders Approve Meeting Agenda - TipRanks
Merger Between NLS Pharmaceutics and Kadimastem Advances with SEC Filing - Sleep Review
What's Going On With NLS Pharmaceuticals Stock Monday? - Benzinga
NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans - TipRanks
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - IT News Online
NLS Pharmaceutics and Kadimastem Advance Merger Plans with SEC Registration for CNS Drug Development - StockTitan
NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring - TipRanks
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Advances Revolutionary Type 1 Diabetes Treatment, Seeks FDA Pre-IND Meeting - StockTitan
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLS Pharmaceutics expects to close Kadimastem merger by end of January - Yahoo Finance
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com Nigeria
NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger - Sleep Review
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans - TipRanks
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):